Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ONCY logo

Oncolytics Biotech Inc (ONCY)

Upturn stock ratingUpturn stock rating
Oncolytics Biotech Inc
$0.88
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/09/2024: ONCY (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -17.31%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 28
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/09/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -17.31%
Avg. Invested days: 28
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/09/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 68.09M USD
Price to earnings Ratio -
1Y Target Price 4.92
Dividends yield (FY) -
Basic EPS (TTM) -0.25
Volume (30-day avg) 339534
Beta 1.51
52 Weeks Range 0.84 - 1.53
Updated Date 12/10/2024
Company Size Small-Cap Stock
Market Capitalization 68.09M USD
Price to earnings Ratio -
1Y Target Price 4.92
Dividends yield (FY) -
Basic EPS (TTM) -0.25
Volume (30-day avg) 339534
Beta 1.51
52 Weeks Range 0.84 - 1.53
Updated Date 12/10/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -71.33%
Return on Equity (TTM) -138.22%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 54991255
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.79
Shares Outstanding 77074096
Shares Floating 73758778
Percent Insiders 3.82
Percent Institutions 1.76
Trailing PE -
Forward PE -
Enterprise Value 54991255
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.79
Shares Outstanding 77074096
Shares Floating 73758778
Percent Insiders 3.82
Percent Institutions 1.76

Analyst Ratings

Rating 4.38
Target Price 7.33
Buy 5
Strong Buy 3
Hold -
Sell -
Strong Sell -
Rating 4.38
Target Price 7.33
Buy 5
Strong Buy 3
Hold -
Sell -
Strong Sell -

AI Summarization

Oncolytics Biotech Inc. (ONCY): A Comprehensive Overview

Company Profile:

History and Background: Oncolytics Biotech Inc. (ONCY) is a Calgary, Canada-based biotechnology company focused on developing and commercializing oncolytic virotherapy to treat various cancers. Founded in 1998, the company has over two decades of experience in this field.

Core Business Areas: ONCY's primary focus is on its proprietary oncolytic virus, reolysin® (pelareorep). The company's business model revolves around:

  • Developing reolysin® for various cancer indications: ONCY is currently exploring its application in various cancers, including head and neck squamous cell carcinoma (HNSCC), melanoma, and pancreatic cancer.
  • Out-licensing reolysin® technology: ONCY partners with other pharmaceutical companies to further develop and commercialize reolysin® for specific cancer indications.

Leadership and Corporate Structure: The company is led by Dr. Matt Coffey, President and CEO. ONCY has a Board of Directors and a management team with expertise in drug development, commercialization, and finance.

Top Products and Market Share:

Top Products:

  • reolysin® (pelareorep): This is ONCY's lead product, an oncolytic virus that selectively infects and destroys cancer cells while sparing healthy tissues.
  • Reolysin®-based combination therapies: ONCY is also exploring the potential of combining reolysin® with other cancer treatments, such as chemotherapy and immunotherapy.

Market Share: As a clinical-stage company, ONCY does not currently have any marketed products. Its market share is therefore non-existent at this time.

Product Performance and Market Reception: reolysin® has shown promising results in early-stage clinical trials, demonstrating safety and efficacy in treating various cancers. However, it is still in the development phase and has not yet received regulatory approval for any indication.

Total Addressable Market: The global oncolytic virus therapy market is projected to reach $1.4 billion by 2025, indicating significant growth potential for this therapy approach.

Financial Performance:

Recent Financial Statements: ONCY is a pre-revenue company, meaning it has not yet generated any sales from its products. Therefore, it currently reports net losses.

Year-over-Year Performance: ONCY's operating expenses have been increasing in recent years due to ongoing clinical trials and development activities. However, the company is actively seeking funding through partnerships and collaborations to support its growth.

Cash Flow and Balance Sheet: ONCY has a limited cash runway, and its long-term financial viability depends on securing additional funding. Its balance sheet primarily reflects cash and investments.

Dividends and Shareholder Returns: ONCY is a pre-revenue company and does not currently pay dividends. Its stock price has been volatile in recent years, reflecting the inherent risk associated with early-stage biotech companies.

Growth Trajectory:

Historical Growth: ONCY's historical growth has been primarily driven by advancements in its clinical trials and development programs.

Future Growth Projections: The company's future growth potential is contingent upon the success of its ongoing clinical trials and its ability to secure regulatory approvals for reolysin®.

Growth Drivers:

  • Positive clinical trial results for reolysin®
  • Regulatory approvals for reolysin®
  • Strategic partnerships and collaborations with other pharmaceutical companies

Market Dynamics:

Industry Overview: The oncolytic virus therapy market is still in its early stages of development but holds significant promise for the future of cancer treatment.

ONCY's Position: ONCY is a pioneer in the field of oncolytic virus therapy and is at the forefront of developing this innovative approach.

Market Adaptability: The company is actively adapting to the evolving market landscape by exploring various combination therapies and partnering with other industry players.

Competitors:

  • Amgen (AMGEN)
  • Merck (MRK)
  • Bristol Myers Squibb (BMY)
  • Iovance Biotherapeutics (IOVA)

Competitive Advantages:

  • Proprietary oncolytic virus platform (reolysin®)
  • Strong clinical data supporting the efficacy and safety of reolysin®
  • Experienced leadership team with a proven track record

Competitive Disadvantages:

  • Pre-revenue stage with no approved products
  • Limited financial resources
  • Intense competition from larger pharmaceutical companies

Potential Challenges and Opportunities:

Key Challenges:

  • Funding and cash runway limitations
  • Regulatory hurdles and lengthy approval processes
  • Competition from established players in the pharmaceutical industry

Key Opportunities:

  • Promising clinical data for reolysin®
  • Growing market for oncolytic virus therapy
  • Potential for lucrative partnerships and collaborations

Recent Acquisitions (last 3 years):

ONCY has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Rating: 7/10

Justification: ONCY has a strong fundamental base with a promising product candidate and a dedicated team. However, its pre-revenue stage and limited financial resources present significant risks for investors. The company's future success will depend on the outcome of its ongoing clinical trials and its ability to secure partnerships and funding.

Sources and Disclaimers:

  • This analysis utilizes information from ONCY's website, financial reports, and publicly available market research.
  • This information is provided for educational purposes only and should not be considered investment advice. It is essential to conduct your own due diligence before making any investment decisions.

Disclaimer: I am an AI chatbot and cannot provide financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Oncolytics Biotech Inc

Exchange NASDAQ Headquaters Calgary, AB, Canada
IPO Launch date 1999-11-08 Interim CEO & Chairman of the Board Mr. Wayne F. Pisano M.B.A.
Sector Healthcare Website https://www.oncolyticsbiotech.com
Industry Biotechnology Full time employees -
Headquaters Calgary, AB, Canada
Interim CEO & Chairman of the Board Mr. Wayne F. Pisano M.B.A.
Website https://www.oncolyticsbiotech.com
Website https://www.oncolyticsbiotech.com
Full time employees -

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​